| scholarly article | Q13442814 |
| P50 | author | Justin Albert | Q79190038 |
| P2093 | author name string | Mason N | |
| Arab L | |||
| Akizawa T | |||
| Akiba T | |||
| Young EW | |||
| Pisoni RL | |||
| Jadoul M | |||
| Bragg-Gresham JL | |||
| Prutz KG | |||
| P2860 | cites work | Effect of folate and mecobalamin on hip fractures in patients with stroke: a randomized controlled trial | Q28237610 |
| Homocysteine levels and the risk of osteoporotic fracture | Q28261532 | ||
| Homocysteine as a predictive factor for hip fracture in older persons | Q28261544 | ||
| Diabetes mellitus and the risk of non-vertebral fractures: the Tromsø study | Q33226999 | ||
| Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. | Q34319046 | ||
| Benzodiazepines and risk of hip fractures in older people: a review of the evidence | Q35201021 | ||
| Use of beta-blockers and risk of fractures | Q38477375 | ||
| Central nervous system-active medications and risk for falls in older women | Q40628780 | ||
| Drugs and falls in older people: a systematic review and meta-analysis: I. Psychotropic drugs. | Q40827242 | ||
| Central nervous system active medications and risk for fractures in older women | Q44420332 | ||
| Exposure to tricyclic and selective serotonin reuptake inhibitor antidepressants and the risk of hip fracture | Q44497585 | ||
| Use of statins and fracture: results of 4 prospective studies and cumulative meta-analysis of observational studies and controlled trials. | Q45978371 | ||
| Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism | Q46704863 | ||
| Risk factors for hip fractures in a middle-aged population: a study of 33,000 men and women | Q46715561 | ||
| Mineral metabolism, mortality, and morbidity in maintenance hemodialysis | Q50144395 | ||
| Use of selective serotonin-reuptake inhibitors or tricyclic antidepressants and risk of hip fractures in elderly people. | Q50879873 | ||
| Falls in hemodialysis patients: prospective study of incidence, risk factors, and complications. | Q53278375 | ||
| PTH and the risks for hip, vertebral, and pelvic fractures among patients on dialysis. | Q53607251 | ||
| International variations in hip fracture probabilities: implications for risk assessment | Q57215208 | ||
| Predictors of hip fractures in elderly men | Q71053215 | ||
| Drugs and falls in later life | Q72991348 | ||
| Risk factors for hip fracture among patients with end-stage renal disease | Q73108274 | ||
| Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone | Q73235636 | ||
| Increased risk of hip fracture among patients with end-stage renal disease | Q73969374 | ||
| Risk of hip fracture among dialysis and renal transplant recipients | Q78651051 | ||
| Increased risk of mortality associated with hip fracture in the dialysis population | Q80598163 | ||
| Screening for depression in hemodialysis patients: associations with diagnosis, treatment, and outcomes in the DOPPS | Q80888550 | ||
| Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study | Q81376661 | ||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | bone fracture | Q68833 |
| patient | Q181600 | ||
| renal dialysis | Q202301 | ||
| hemodialysis patient | Q126109077 | ||
| P304 | page(s) | 1358-1366 | |
| P577 | publication date | 2006-08-23 | |
| P1433 | published in | Kidney International | Q6404823 |
| P1476 | title | Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study | |
| P478 | volume | 70 |
| Q48118406 | A Decision-Analytic Model to Assess the Cost-Effectiveness of Etelcalcetide vs. Cinacalcet. |
| Q90236256 | A Systematic Review and Meta-analysis of the Association Between Vitamin K Antagonist Use and Fracture |
| Q30313255 | A comparative study of bone biopsies from the iliac crest, the tibial bone, and the lumbar spine |
| Q42633291 | A cost-utility analysis of cinacalcet in secondary hyperparathyroidism in five European countries |
| Q36957417 | Are physicians ready to prevent osteoporotic fractures in hemodialysis patients? |
| Q89280865 | Association of renal function with bone mineral density and fracture risk in the Longitudinal Aging Study Amsterdam |
| Q90466186 | Associations of Opioid Prescriptions with Death and Hospitalization across the Spectrum of Estimated GFR |
| Q39254025 | Biomarkers Predicting Bone Turnover in the Setting of CKD. |
| Q37986588 | Bone and kidney disease: diagnostic and therapeutic implications |
| Q47738927 | Bone and mineral disorders in chronic kidney disease: implications for cardiovascular health and ageing in the general population. |
| Q90328403 | Bone biopsy in nephrology practice |
| Q40275241 | Bone biopsy practice patterns across Europe: the European renal osteodystrophy initiative-a position paper |
| Q90305128 | Bone fragility in patients with chronic kidney diseases |
| Q53155783 | Bone microarchitecture is more severely affected in patients on hemodialysis than in those receiving peritoneal dialysis. |
| Q44608625 | Bone mineral density and parathyroid function in patients on maintenance hemodialysis |
| Q37663859 | Bone mineral density in patients on maintenance dialysis |
| Q37182739 | Calcimimetics in chronic kidney disease: evidence, opportunities and challenges |
| Q48484505 | Charlson co-morbidity index and albumin significantly associated with fracture risk in peritoneal dialysis patients |
| Q38678632 | Chronic Kidney Disease-Mineral Bone Disorder in the Elderly Peritoneal Dialysis Patient |
| Q92533944 | Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD): Current Perspectives |
| Q34069692 | Chronic kidney disease and bone fracture: a growing concern |
| Q86663695 | Chronic kidney disease and bone metabolism |
| Q35755179 | Chronic kidney disease and the skeleton |
| Q48323760 | Chronic kidney disease and vitamin D metabolism in human bone marrow-derived MSCs |
| Q37916534 | Cinacalcet: a pharmacoeconomic review of its use in secondary hyperparathyroidism in end-stage renal disease |
| Q35030613 | Clinical efficacy and cost-effectiveness of lanthanum carbonate as second-line therapy in hemodialysis patients in Japan. |
| Q43427754 | Clinical practice guideline for the management of chronic kidney disease-mineral and bone disorder |
| Q87860874 | Compared effects of calcium and sodium polystyrene sulfonate on mineral and bone metabolism and volume overload in pre-dialysis patients with hyperkalemia |
| Q38691202 | Comparison between paricalcitol and active non-selective vitamin D receptor activator for secondary hyperparathyroidism in chronic kidney disease: a systematic review and meta-analysis of randomized controlled trials |
| Q53780644 | Compliance with mineral metabolism targets in haemodialysis patients: moving backwards? |
| Q93203333 | Death and Postoperative Complications After Hip Fracture Repair: Dialysis Effect |
| Q35983513 | Decreases in PTH in Japanese hemodialysis patients with secondary hyperparathyroidism: associations with changing practice patterns. |
| Q40296289 | Dementia is a major risk factor for hip fractures in patients with chronic kidney disease |
| Q36645688 | Diagnosis of low bone mass in CKD-5D patients |
| Q35804178 | Differences in bone quality in low- and high-turnover renal osteodystrophy |
| Q92527063 | Differences in quality of life and cognition between the elderly and the very elderly hemodialysis patients |
| Q35142758 | Discriminants of prevalent fractures in chronic kidney disease |
| Q37912038 | Diseases of the parathyroid gland in chronic kidney disease. |
| Q42856989 | Economic Analysis of Cinacalcet in Combination With Low-Dose Vitamin D Versus Flexible-Dose Vitamin D in Treating Secondary Hyperparathyroidism in Hemodialysis Patients |
| Q42678184 | Economic Evaluation of Cinacalcet in the Treatment of Secondary Hyperparathyroidism in Italy |
| Q35658608 | Effects of Cinacalcet on Fracture Events in Patients Receiving Hemodialysis: The EVOLVE Trial |
| Q53662466 | Effects of raloxifene on bone metabolism in postmenopausal women on chronic hemodialysis. |
| Q38797594 | Emerging role of high-resolution imaging in the detection of renal osteodystrophy. |
| Q37065614 | Estimated GFR and fracture risk: a population-based study |
| Q39225909 | Evaluation of fracture risk in chronic kidney disease. |
| Q93059879 | Evaluation of the association of Wnt signaling with coronary artery calcification in patients on dialysis with severe secondary hyperparathyroidism |
| Q38627241 | Exploring the potential value of improved care for secondary hyperparathyroidism with a novel calcimimetic therapy. |
| Q35848034 | Femoral bone mineral density reflects histologically determined cortical bone volume in hemodialysis patients |
| Q40876941 | Fibromyalgia and its clinical relevance in renal transplant recipients |
| Q50804214 | Fibromyalgia: its prevalence and impact on the quality of life on a hemodialyzed population. |
| Q30703135 | Fracture Burden and Risk Factors in Childhood CKD: Results from the CKiD Cohort Study |
| Q64989241 | Fracture Risk in Dialysis and Kidney Transplanted Patients: A Systematic Review. |
| Q43063365 | Fracture risk in CKD. |
| Q39946556 | Frequent monitoring of mineral metabolism in hemodialysis patients with secondary hyperparathyroidism: associations with achievement of treatment goals and with adjustments in therapy |
| Q89000326 | Gabapentin and Pregabalin Use and Association with Adverse Outcomes among Hemodialysis Patients |
| Q39705072 | Geovariation in Fracture Risk among Patients Receiving Hemodialysis |
| Q35804097 | Health state utilities associated with major clinical events in the context of secondary hyperparathyroidism and chronic kidney disease requiring dialysis |
| Q41087108 | High mortality after pelvis and lower limb fractures in ESRD. |
| Q46906565 | High prevalence of vertebral fractures assessed by quantitative morphometry in hemodialysis patients, strongly associated with vascular calcifications |
| Q37542005 | High rates of death and hospitalization follow bone fracture among hemodialysis patients |
| Q39342144 | Higher serum sclerostin levels and insufficiency of vitamin D are strongly associated with vertebral fractures in hemodialysis patients: a case control study. |
| Q93089365 | Hip hemiarthroplasty for femoral neck fractures in end-stage renal disease patients on dialysis compared to patients with late-stage chronic kidney disease |
| Q51191871 | Impact of long-term cinacalcet, ibandronate or teriparatide therapy on bone mineral density of hemodialysis patients: a pilot study. |
| Q34459406 | Impact of mineral and bone disorder on healthcare resource use and associated costs in the European Fresenius medical care dialysis population: a retrospective cohort study |
| Q44635041 | Incidence and risk factors for hip fractures in dialysis patients |
| Q51282990 | Increased risk of hip fracture among Japanese hemodialysis patients. |
| Q37446664 | Increasing dietary phosphorus intake from food additives: potential for negative impact on bone health |
| Q38828618 | Integral pharmacological management of bone mineral disorders in chronic kidney disease (part II): from treatment of phosphate imbalance to control of PTH and prevention of progression of cardiovascular calcification |
| Q88636839 | Inverse relationship of bone mineral density and serum level of N-terminal pro-B-type natriuretic peptide in peritoneal dialysis patients |
| Q89942757 | Is There a Gender Difference in Clinical Presentation of Renal Hyperparathyroidism and Outcome after Parathyroidectomy? |
| Q38423741 | Is the dialysate calcium concentration of 1.75 mmol/L suitable for Chinese patients on maintenance hemodialysis? |
| Q36495030 | Kidney Function and Fracture Risk: The Atherosclerosis Risk in Communities (ARIC) Study |
| Q47256900 | Lesion based diagnostic performance of dual phase 99mTc-MIBI SPECT/CT imaging and ultrasonography in patients with secondary hyperparathyroidism |
| Q52723485 | Long-term effects of low calcium dialysates on the serum calcium levels during maintenance hemodialysis treatments: A systematic review and meta-analysis. |
| Q48207264 | Magnesium and Risk of Hip Fracture among Patients Undergoing Hemodialysis. |
| Q37547201 | Management of secondary hyperparathyroidism in the elderly patient with chronic kidney disease. |
| Q38775426 | Management of secondary hyperparathyroidism: how and why? |
| Q57021200 | Mineral and bone disorder management in hemodialysis patients: comparing PTH control practices in Japan with Europe and North America: the Dialysis Outcomes and Practice Patterns Study (DOPPS) |
| Q36994038 | Mineral metabolic abnormalities and mortality in dialysis patients |
| Q37050485 | Mineral metabolism and bone abnormalities in children with chronic renal failure |
| Q33878430 | Mineral metabolism management in hemodialysis patients with secondary hyperparathyroidism in Japan: baseline data from the MBD-5D. |
| Q35684700 | Mortality and complications after hip fracture among elderly patients undergoing hemodialysis |
| Q63427982 | No difference between alfacalcidol and paricalcitol in the treatment of secondary hyperparathyroidism in hemodialysis patients: a randomized crossover trial |
| Q50917530 | Not only for the risk of bone fracture. |
| Q93044584 | Novel insights into parathyroid hormone: report of The Parathyroid Day in Chronic Kidney Disease |
| Q52576665 | Opioid Analgesics and Adverse Outcomes among Hemodialysis Patients. |
| Q38878717 | Opioid Use in Chronic Pain Patients with Chronic Kidney Disease: A Systematic Review |
| Q34639629 | Opioid and benzodiazepine use in end-stage renal disease: a systematic review |
| Q30235173 | Osteoporosis in Frail Patients: A Consensus Paper of the Belgian Bone Club. |
| Q39014553 | Osteoporosis in patients with diabetes after kidney transplantation |
| Q39255870 | Osteoporosis, bone mineral density and CKD-MBD: treatment considerations. |
| Q97530990 | Osteoporotic fracture rates in chronic hemodialysis and effect of heparin exposure: a retrospective cohort study |
| Q38771730 | Osteoporotic fractures in patients with systemic lupus erythematosus and end stage renal disease |
| Q38187185 | Pain in chronic kidney disease: a scoping review |
| Q43174153 | Pain, analgesics, and safety in patients with CKD. |
| Q39156700 | Parathyroid hormone targets in chronic kidney disease and managing severe hyperparathyroidism. |
| Q84962504 | Parathyroid scintigraphy findings in chronic kidney disease patients with recurrent hyperparathyroidism |
| Q44834439 | Persistent hyperparathyroidism is a major risk factor for fractures in the five years after kidney transplantation |
| Q42566449 | Pin1 regulates parathyroid hormone mRNA stability |
| Q36199558 | Prescription patterns and mineral metabolism abnormalities in the cinacalcet era: results from the MBD-5D study |
| Q34435887 | Pro-inflammatory cytokines and bone fractures in CKD patients. An exploratory single centre study |
| Q36072533 | Relationship between Fetuin A, Vascular Calcification and Fracture Risk in Dialysis Patients |
| Q38105272 | Renale osteodystrophie |
| Q59126536 | Rethinking Bone Disease in Kidney Disease |
| Q38141236 | Review of cinacalcet hydrochloride in the management of secondary hyperparathyroidism. |
| Q38530298 | Sclerostin and DKK1: new players in renal bone and vascular disease |
| Q40996542 | Second Chances to Improve ESRD Outcomes With a Second-Generation Calcimimetic |
| Q48283940 | Serum Parathyroid Hormone Concentrations and Clinical Outcomes in ESRD: A Call for Targeted Clinical Trials |
| Q40344912 | Serum Phosphate Is Associated With Fracture Risk: The Rotterdam Study and MrOS. |
| Q91964524 | Serum sclerostin levels are positively related to bone mineral density in peritoneal dialysis patients: a cross-sectional study |
| Q38595572 | Should chronic metabolic acidosis be treated in older people with chronic kidney disease? |
| Q33995995 | Should teriparatide ever be used for adynamic bone disease? |
| Q40105699 | Statins are associated with a reduced risk of bone fracture in hemodialysis (HD) patients |
| Q37119913 | Temporal trends in fracture rates and postdischarge outcomes among hemodialysis patients |
| Q37065632 | Temporal trends in the incidence, treatment, and outcomes of hip fracture in older patients initiating dialysis in the United States |
| Q41261277 | The Effect of Parathyroidectomy on Risk of Hip Fracture in Secondary Hyperparathyroidism |
| Q41408549 | The FRAX ® as a predictor of mortality in Japanese incident hemodialysis patients: an observational, follow-up study |
| Q95501922 | The authors reply |
| Q33939447 | The elderly patients on hemodialysis |
| Q37821623 | The regulation of parathyroid hormone secretion and synthesis |
| Q44741994 | The three-year incidence of fracture in chronic kidney disease. |
| Q50146635 | The utility of FRAX® in predicting bone fractures in patients with chronic kidney disease on hemodialysis: a two-year prospective multicenter cohort study |
| Q49375971 | Two-year cortical and trabecular bone loss in CKD-5D: biochemical and clinical predictors |
| Q48197934 | Update on the role of bone biopsy in the management of patients with CKD-MBD. |
| Q42727513 | Uremic osteoporosis |
| Q35391160 | Use of renin-angiotensin system inhibitors is associated with reduction of fracture risk in hemodialysis patients. |
| Q37090796 | Vascular calcifications, vertebral fractures and mortality in haemodialysis patients |
| Q37763820 | Vertebral fractures in dialysis: Endocrinological disruption of the bone-kidney axis |
| Q37620414 | Vitamin D and chronic kidney disease-mineral bone disease (CKD-MBD). |
| Q45016048 | Vitamin D insufficiency and bone fractures in patients on maintenance hemodialysis |
| Q37357929 | Vitamin K status in chronic kidney disease |
| Q37810737 | Vitamin K, bone fractures, and vascular calcifications in chronic kidney disease: An important but poorly studied relationship |
| Q56639257 | Vitamin K, vertebral fractures, vascular calcifications, and mortality: VItamin K Italian (VIKI) dialysis study |
| Q37941837 | Vitamin d and stage 5 chronic kidney disease: a new paradigm? |
| Q83927291 | [Bone and parathormone: which PTH blood concentration in the dialyzed patient?] |
Search more.